• Monday, Jan 18, 2021
  • Last Update : 11:54 pm

Serum Institute to focus on supplying Covid-19 vaccine to India first

  • Published at 02:56 pm November 24th, 2020
AstraZeneca vaccine
File photo: Vials with a sticker are seen in front of a displayed AstraZeneca logo in this illustration taken on October 31, 2020 Reuters

The company will be able to produce 400 million doses of AstraZeneca's vaccine by July 2021

The Serum Institute of India, the world's largest manufacturer of vaccines by volume, will first focus on supplying AstraZeneca Plc's Covid-19 vaccine to Indians before distributing it to other countries, Serum's Chief Executive Adar Poonawalla said on Monday.

"It's very important we take care of our country first, then go on to Covax after that and then other bilateral deals with countries. So I've kept it in that priority," said Poonawalla, referencing the global Covax facility, which has been set up to provide Covid-19 vaccines to poorer countries.

The company remains in discussion with the Indian government about inking a purchase agreement for the vaccine, Poonawalla said in an interview with CNBC-TV 18, adding that Serum should have quantities of it ready to sell into India's private market in the first quarter of 2021.

Poonawalla's comments came shortly after AstraZeneca said on Monday its vaccine could be around 90% effective, giving the world's fight against the pandemic a new weapon, cheaper to make, easier to distribute and faster to scale up than rivals.

Serum is hoping the data released earlier on Monday, along with preliminary data from the ongoing trial of the vaccine in India, will allow it to seek emergency use authorization for the vaccine by year-end, before gaining approval for a full rollout by February or March next year, said Poonawalla.

He said the vaccine in the Indian private market would be priced at 1,000 rupees per dose ($13.50), but that governments signing large supply deals would likely buy it at lower prices.

Poonawalla also said that although Serum has the right to strike direct bilateral deals with more than five dozen nations, on the basis of its licensing deal with AstraZeneca, the company may include the government in some of these discussions.

Poonawalla said the company will be able to produce 400 million doses of AstraZeneca's vaccine by July 2021 and scale up further from there.

 

52
Facebook 51
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail